Skip to main content
Fig. 5 | BMC Research Notes

Fig. 5

From: NSP4 as adjuvant for immunogenicity and design of effective therapeutic HPV16 E6/E7/L1 DNA vaccine in tumor-bearing and healthy C57BL/6 mice

Fig. 5

Co-administration of the NSP4 adjuvant with a E6/E/L1 vaccine induced significantly higher amounts of IFN-γ, IL-4 and IL-12 in vivo. The supernatants of splenocytes, stimulated with PHA and TC-1, from each group were collected one week after the third immunization. ELISA was performed to detect the level of IFN-γ (A), IL-4 (B), IL-12 (C) in splenocyte cultures. All of cytokines were significantly higher in E6-E7-L1 / NSP4 group and E6-E7-L1 group compared to other groups

Back to article page